Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sorafenib With Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas

NCT02050919 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT02050919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02050919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sorafenib With Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
December 3, 2013
Completion date
December 31, 2020
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pleomorphic rhabdomyosarcoma, stage iib adult soft tissue sarcoma ajcc v7, stage iii adult soft tissue sarcoma ajcc v7, stage iv adult soft tissue sarcoma ajcc v7